ESMO2018 演題レポート Madrid, Spain 08 Sep - 12 Sep 2018

2018年10月19日~23日にドイツ・ミュンヘンで開催された 2018年 欧州臨床腫瘍学会学術集会(ESMO 2018 Congress)より、大腸癌や胃癌などの消化器癌の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。



Proffered Paper Session

Abstract #LBA18_PR

Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal Cancer (mCRC).

Heinz-Josef J. Lenz, et al.

Abstract #LBA19

Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL ? a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy

Axel Grothey, et al.

Abstract #LBA20

TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts).

Chiara Cremolini, et al.

Abstract #LBA25

TAGS: a phase 3, randomised, double-blind study of trifluridine/tipiracil (TAS-102) versus placebo in patients with refractory metastatic gastric cancer.

Hendrik-Tobias Arkenau, et al.

Abstract #LBA26

Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC).

Michael J. Pishvaian, et al.

Abstract #LBA27

A Randomized Multicentered Phase 2 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects with Advanced Hepatocellular Carcinoma (HCC) who Failed or Intolerable to Prior Systemic Treatment.

Shu-Kui Qin, et al.

Abstract #50O

Plasma cell-free DNA (cfDNA) assays for early multi-cancer detection: the Circulating Cell-Free Genome Atlas (CCGA) study.

Minetta C. Liu, et al.

Abstract #615O

Randomized phase III study of Gemcitabine, Cisplatin plus S-1 (GCS) versus Gemcitabine, Cisplatin (GC) for Advanced Biliary Tract Cancer (KHBO1401-MITSUBA).

Daisuke Sakai, et al.

Poster Discussion Session

Abstract #LBA28

Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions.

Milind Javle, et al.

Abstract #453PD

1st-line mFOLFOXIRI + Panitumumab vs FOLFOXIRI treatment of RAS wt mCRC: a randomized phase II VOLFI trial of the AIO (KRK-0109).

Michael Geissler, et al.

Abstract #454PD

Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer.

Hiroya Taniguchi, et al.

Abstract #617PD

A phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastric esophageal junction (G/GEJ) cancer (ATTRACTION-2): Two-years update data.

Taroh Satoh, et al.

Abstract #620PD

Influence of enteral nutrition on nutritional status, treatment toxicities, and short-term outcomes in esophageal carcinoma patients treated with concurrent chemoradiotherapy: a prospective, multicenter, randomized controlled study.

Tao Li, et al.

Poster Display Session

Abstract #467P

Prospective Evaluation of Regorafenib Dose Escalation Strategy with Low Starting Dose in Patients with Colorectal Cancer.

Toshiki Masuishi, et al.

Abstract #563P

Updated results of phase 1 study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer.

Takayuki Yoshino, et al.

Abstract #667P

A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2-positive advanced gastric cancer (HIGHSOX).

Keisho Chin, et al.

Abstract #668P

Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B.

Satoshi Yuki, et al.